Literature DB >> 31974144

Glucagon Resistance at the Level of Amino Acid Turnover in Obese Subjects With Hepatic Steatosis.

Malte P Suppli1, Jonatan I Bagger1, Asger Lund1, Mia Demant1, Gerrit van Hall2,3, Charlotte Strandberg4, Merete J Kønig4, Kristoffer Rigbolt5, Jill L Langhoff6, Nicolai J Wewer Albrechtsen2,7,8,9, Jens J Holst2,7, Tina Vilsbøll1,10,11, Filip K Knop12,7,10,11.   

Abstract

Glucagon secretion is regulated by circulating glucose, but it has turned out that amino acids also play an important role and that hepatic amino acid metabolism and glucagon are linked in a mutual feedback cycle, the liver-α-cell axis. On the basis of this knowledge, we hypothesized that hepatic steatosis might impair glucagon's action on hepatic amino acid metabolism and lead to hyperaminoacidemia and hyperglucagonemia. We subjected 15 healthy lean and 15 obese steatotic male participants to a pancreatic clamp with somatostatin and evaluated hepatic glucose and amino acid metabolism when glucagon was at basal levels and at high physiological levels. The degree of steatosis was evaluated from liver biopsy specimens. Total RNA sequencing of liver biopsy specimens from the obese steatotic individuals revealed perturbations in the expression of genes predominantly involved in amino acid metabolism. This group was characterized by fasting hyperglucagonemia, hyperaminoacidemia, and no lowering of amino acid levels in response to high levels of glucagon. Endogenous glucose production was similar between lean and obese individuals. Our results suggest that hepatic steatosis causes resistance to the effect of glucagon on amino acid metabolism. This results in increased amino acid concentrations and increased glucagon secretion, providing a likely explanation for fatty liver-associated hyperglucagonemia.
© 2020 by the American Diabetes Association.

Entities:  

Year:  2020        PMID: 31974144     DOI: 10.2337/db19-0715

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  10 in total

1.  Insulin secretion and action and the response of endogenous glucose production to a lack of glucagon suppression in nondiabetic subjects.

Authors:  Jon D Adams; Aoife M Egan; Marcello C Laurenti; Daniel Schembri Wismayer; Kent R Bailey; Claudio Cobelli; Chiara Dalla Man; Adrian Vella
Journal:  Am J Physiol Endocrinol Metab       Date:  2021-10-18       Impact factor: 4.310

Review 2.  Physiological significance of bistable circuit design in metabolic homeostasis: role of integrated insulin-glucagon signalling network.

Authors:  Manu Tomar; Pramod R Somvanshi; Venkatesh Kareenhalli
Journal:  Mol Biol Rep       Date:  2022-01-25       Impact factor: 2.742

Review 3.  NAFLD as a continuum: from obesity to metabolic syndrome and diabetes.

Authors:  Amélio F Godoy-Matos; Wellington S Silva Júnior; Cynthia M Valerio
Journal:  Diabetol Metab Syndr       Date:  2020-07-14       Impact factor: 3.320

4.  Impaired Suppression of Glucagon in Obese Subjects Parallels Decline in Insulin Sensitivity and Beta-Cell Function.

Authors:  Xi Chen; Enrique Maldonado; Ralph A DeFronzo; Devjit Tripathy
Journal:  J Clin Endocrinol Metab       Date:  2021-04-23       Impact factor: 5.958

Review 5.  Amylin and Calcitonin: Potential Therapeutic Strategies to Reduce Body Weight and Liver Fat.

Authors:  David S Mathiesen; Asger Lund; Tina Vilsbøll; Filip K Knop; Jonatan I Bagger
Journal:  Front Endocrinol (Lausanne)       Date:  2021-01-08       Impact factor: 5.555

6.  The liver-alpha cell axis associates with liver fat and insulin resistance: a validation study in women with non-steatotic liver fat levels.

Authors:  Christina Gar; Stefanie J Haschka; Stefanie Kern-Matschilles; Barbara Rauch; Vanessa Sacco; Cornelia Prehn; Jerzy Adamski; Jochen Seissler; Nicolai J Wewer Albrechtsen; Jens J Holst; Andreas Lechner
Journal:  Diabetologia       Date:  2020-12-04       Impact factor: 10.122

7.  Obesity attenuates inflammation, protein catabolism, dyslipidaemia, and muscle weakness during sepsis, independent of leptin.

Authors:  Wouter Vankrunkelsven; Sarah Derde; Jan Gunst; Sarah Vander Perre; Emiel Declerck; Lies Pauwels; Inge Derese; Greet Van den Berghe; Lies Langouche
Journal:  J Cachexia Sarcopenia Muscle       Date:  2022-01-07       Impact factor: 12.910

8.  High Protein Diet Feeding Aggravates Hyperaminoacidemia in Mice Deficient in Proglucagon-Derived Peptides.

Authors:  Shinji Ueno; Yusuke Seino; Shihomi Hidaka; Ryuya Maekawa; Yuko Takano; Michiyo Yamamoto; Mika Hori; Kana Yokota; Atsushi Masuda; Tatsuhito Himeno; Shin Tsunekawa; Hideki Kamiya; Jiro Nakamura; Hitoshi Kuwata; Haruki Fujisawa; Megumi Shibata; Takeshi Takayanagi; Yoshihisa Sugimura; Daisuke Yabe; Yoshitaka Hayashi; Atsushi Suzuki
Journal:  Nutrients       Date:  2022-02-25       Impact factor: 5.717

9.  Hepatic microbiome in healthy lean and obese humans.

Authors:  Malte Palm Suppli; Jonatan Ising Bagger; Benjamin Lelouvier; Amandine Broha; Mia Demant; Merete Juhl Kønig; Charlotte Strandberg; Asger Lund; Tina Vilsbøll; Filip Krag Knop
Journal:  JHEP Rep       Date:  2021-04-27

10.  Neprilysin Inhibition Increases Glucagon Levels in Humans and Mice With Potential Effects on Amino Acid Metabolism.

Authors:  Sasha A S Kjeldsen; Lasse H Hansen; Nathalie Esser; Steve Mongovin; Marie Winther-Sørensen; Katrine D Galsgaard; Jenna E Hunt; Hannelouise Kissow; Frederik R Ceutz; Dijana Terzic; Peter D Mark; Peter Plomgaard; Jens P Goetze; Gijs H Goossens; Ellen E Blaak; Carolyn F Deacon; Mette M Rosenkilde; Sakeneh Zraika; Jens J Holst; Nicolai J Wewer Albrechtsen
Journal:  J Endocr Soc       Date:  2021-05-16
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.